STOCK TITAN

Moderna, Inc. - MRNA STOCK NEWS

Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.

Moderna, Inc. (NASDAQ: MRNA) is a cutting-edge biotech company based in Cambridge, Massachusetts, founded in 2010. Moderna is at the forefront of pioneering messenger RNA therapeutics™, a revolutionary class of drugs that utilize mRNA technology to direct cells to produce proteins that can fight diseases. This innovative approach has shown promise in addressing targets that were previously considered untreatable with traditional drugs.

With over 200 patent applications and more than 10,000 claims, Moderna has a robust intellectual property portfolio that includes novel nucleotide chemistries and specific drug compositions. The company has successfully developed and commercialized several mRNA-based drugs, initially focusing on rare diseases and oncology, while partnering to advance drug candidates in other therapeutic areas.

Moderna’s mRNA technology gained global recognition with its COVID-19 vaccine, Spikevax®, which was one of the earliest vaccines to receive emergency use authorization in the United States in December 2020. As of mid-2023, Moderna had 39 mRNA development candidates in clinical trials, covering a wide range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders.

Some of Moderna's recent achievements include the advancement of three new vaccine programs—targeting Epstein-Barr virus, Varicella-Zoster virus, and norovirus—towards Phase 3 clinical trials. Additionally, the company initiated three new clinical studies combining its investigational individualized neoantigen therapy with Merck’s Keytruda® for treating various cancers.

Financially, Moderna reported first-quarter revenues of $167 million in 2024, with a GAAP net loss of $1.2 billion. Despite the decline in COVID-19 vaccine sales, the company reaffirms its 2024 expected product sales of approximately $4 billion. Moderna is preparing for the launches of its RSV vaccine and the Spikevax® 2024-2025 formula, demonstrating its commitment to fighting respiratory illnesses.

Moderna continues to focus on innovation and operational efficiency, utilizing AI technologies to enhance productivity. The company's long-term vision includes leveraging its mRNA platform to develop therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases, striving to make a significant impact on global health.

Rhea-AI Summary

Moderna (Nasdaq: MRNA) and Uber (NYSE: UBER) have announced a partnership to enhance COVID-19 vaccine uptake. The collaboration will begin with providing vaccine safety information through Uber's app and will explore options like in-app ride scheduling for immunization appointments. Uber previously committed to offering 10 million free or discounted rides to facilitate access to vaccines, especially in underserved communities. Both companies aim to expand this initiative globally, reinforcing vaccine education and accessibility efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
covid-19
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) has appointed José M. Vega, M.D. as its new Chief Safety Officer as of January 11, 2021. Dr. Vega, who brings extensive experience from Merck and Amgen, will oversee safety and pharmacovigilance to ensure high standards of patient safety. His previous roles included leading a global team at Merck and holding significant positions at Amgen. This strategic hire is expected to support Moderna's growth and its commitment to delivering transformative mRNA medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
none
-
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) has received authorization from Swissmedic for its COVID-19 Vaccine in Switzerland. This milestone follows a rigorous examination of data from its Phase 3 clinical study. The Swiss Federal Government has ordered 7.5 million doses, with initial deliveries expected soon. Moderna's COVID-19 vaccine is already authorized in numerous countries, including the U.S. and EU, with ongoing applications under review globally. This approval marks a significant step in Moderna's efforts to combat the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
covid-19
Rhea-AI Summary

Moderna (Nasdaq: MRNA) is actively expanding its innovative vaccine pipeline following the success of its COVID-19 vaccine. The company has announced three new mRNA vaccine candidates targeting seasonal flu, HIV, and the Nipah virus. Additionally, it is broadening its respiratory syncytial virus (RSV) vaccine program to include older adults. CEO Stéphane Bancel highlighted the achievements of 2020 as a pivotal moment for Moderna, boosting confidence in pursuing more ambitious vaccine programs. With 24 mRNA candidates across five therapeutic areas, 13 are currently in clinical stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its COVID-19 vaccine under Regulation 174. This temporary authorization is based on recommendations from the UK Commission on Human Medicines, allowing supply in Great Britain. The UK government has confirmed an additional purchase of 10 million doses, totaling 17 million doses. This marks the fifth jurisdiction to authorize the vaccine, and the first deliveries are expected early in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
covid-19
-
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) announces the appointment of Corinne Le Goff as Chief Commercial Officer, effective January 19, 2021. Le Goff, a seasoned executive from Amgen, will join Moderna's Executive Committee and report to CEO Stéphane Bancel. Her extensive experience includes leadership roles at Amgen, Roche, Sanofi, and Pfizer. Bancel emphasized Le Goff's strategic importance as Moderna shifts to a commercial organization, particularly during the launch of its COVID-19 vaccine and its upcoming CMV vaccine study. Moderna is advancing mRNA science for transformative medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) has received a conditional marketing authorization from the European Commission for its COVID-19 vaccine, allowing widespread vaccination in the EU. This follows recommendations from the European Medicines Agency (EMA) and marks the fourth authorization for the vaccine globally, after the U.S., Canada, and Israel. The EU's confirmed order commitment has increased to 160 million doses. Initial deliveries are expected to commence next week. Moderna highlights its role in tackling the pandemic through its innovative mRNA technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
covid-19
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) announced that Israel’s Ministry of Health has authorized the import of its COVID-19 Vaccine. This marks the vaccine's third regulatory approval, following the U.S. and Canada. Moderna has secured a contract to supply 6 million doses, with deliveries expected to start soon. The decision is based on comprehensive scientific evidence, including data from its Phase 3 clinical study. The vaccine is currently under review for additional authorizations in various countries, including the EU and the UK.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
covid-19
-
Rhea-AI Summary

Moderna (Nasdaq: MRNA) has increased its global production estimate for the COVID-19 Vaccine from 500 million to 600 million doses for 2021. The company aims to scale production to potentially 1 billion doses, expecting 100 million doses available in the U.S. by Q1 2021 and a total of 200 million by the end of Q2 2021. So far, approximately 18 million doses have been supplied to the U.S. government. Moderna has partnerships for production and has secured contracts for 200 million doses with the U.S. and 40 million with Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
covid-19
Rhea-AI Summary

Moderna, Inc. (Nasdaq: MRNA) will present an update on its mRNA development pipeline at the 39th annual J.P. Morgan Healthcare Conference. CEO Stéphane Bancel's presentation is scheduled for January 11, 2021, at 4:30 p.m. ET, accessible via a live webcast on Moderna's investor website. The company continues to advance mRNA science for various diseases through strategic collaborations, including partnerships with AstraZeneca, Merck, and DARPA. Moderna has been recognized as a leading biopharmaceutical employer by Science for six consecutive years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.95%
Tags
none

FAQ

What is the current stock price of Moderna (MRNA)?

The current stock price of Moderna (MRNA) is $35.89 as of January 21, 2025.

What is the market cap of Moderna (MRNA)?

The market cap of Moderna (MRNA) is approximately 14.0B.

What is Moderna’s core business?

Moderna is pioneering mRNA therapeutics and vaccines, focusing on using mRNA technology to direct cells to produce proteins that can treat a wide range of diseases.

What are some recent achievements of Moderna?

Moderna has advanced three new vaccine programs to Phase 3 clinical trials and initiated clinical studies combining individualized neoantigen therapy with Merck’s Keytruda®.

How did Moderna gain global recognition?

Moderna gained global recognition through its COVID-19 vaccine, Spikevax®, which was one of the earliest vaccines to receive emergency use authorization in the United States in December 2020.

What is Moderna’s financial outlook for 2024?

Despite a decline in COVID-19 vaccine sales, Moderna expects 2024 product sales to be approximately $4 billion and is preparing for the launches of its RSV vaccine and the Spikevax® 2024-2025 formula.

What is the significance of Moderna’s mRNA technology?

Moderna’s mRNA technology represents a breakthrough in treating previously untreatable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Where is Moderna headquartered?

Moderna is headquartered in Cambridge, Massachusetts.

How many mRNA development candidates does Moderna have?

As of mid-2023, Moderna had 39 mRNA development candidates in clinical trials.

What areas does Moderna’s mRNA platform cover?

Moderna’s mRNA platform covers therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders.

How is Moderna enhancing its operations?

Moderna is enhancing its operations by utilizing AI technologies to streamline processes and increase productivity.

What is Moderna’s approach to partnerships?

Moderna partners with other companies to develop and commercialize mRNA drugs in various therapeutic areas, aiming to rapidly deliver innovative treatments to patients.
Moderna, Inc.

NYSE:MRNA

MRNA Rankings

MRNA Stock Data

13.97B
348.16M
9.52%
71.57%
10.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE